论文部分内容阅读
目的:研究应用孟鲁司特钠治疗小儿哮喘的临床效果。方法:选取2016年1月-2016年12月期间我院收治的110例小儿哮喘患儿作为临床研究对象,随机将患儿分为实验组和对照组,每组55例,对照组单独采用布地奈德进行治疗,实验组患儿则在对照组治疗基础上加用孟鲁司特钠,比较治疗效果。结果:实验组患儿的治疗总有效率(94.55%)明显高于对照组患儿治疗的总有效率(80.00%),组间数据差异显著,P<0.05,有统计学意义;实验组患儿的不良反应发生率为3.64%,对照组患儿的不良反应发生率为5.45%,组间数据比较未见显著差异,P>0.05,无统计学意义。结论:小儿哮喘治疗中应用孟鲁司特钠,有效缓解了患儿临床症状,同时减少了哮喘发作次数,值得临床推广。
Objective: To study the clinical efficacy of montelukast sodium in the treatment of pediatric asthma. Methods: From January 2016 to December 2016, 110 pediatric asthmatic children admitted to our hospital were selected as the clinical study subjects. The children were randomly divided into experimental group and control group, with 55 cases in each group. The control group was given budesonide alone Ned treatment, the experimental group of children in the control group on the basis of treatment with montelukast sodium, compare the therapeutic effect. Results: The total effective rate (94.55%) in the experimental group was significantly higher than that in the control group (80.00%). There was significant difference between the two groups (P <0.05) The incidence of adverse reactions in children was 3.64%. The incidence of adverse reactions in children in control group was 5.45%. There was no significant difference between the two groups (P> 0.05). There was no statistical significance. Conclusion: The application of montelukast sodium in pediatric asthma treatment effectively relieved the clinical symptoms of children and reduced the number of asthma attacks, which is worthy of clinical promotion.